Search | Invivogen

Human IL-5R Antibody - Benralizumab Biosimilar

Human IgG1 afucosylated - CAS #1044511-01-4

Dose-dependent inhibition of IL-5 signaling using Benralizumab biosimilar

Human CD20 Antibody - Rituximab IgG1fut Isotype

Human IgG1, afucosylated

ADCC assay using various anti-human CD20 (Rituximab) antibody isotypes and Raji-Null target cells

Human CD20 Antibody - Rituximab IgG1NQ Isotype

Human IgG1, Fc silent

ADCC assay using various anti-human CD20 (Rituximab) antibody isotypes and Raji-Null target cells

Human BCMA x E. coli β-Gal Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Evaluation of T cell activation

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-hBCMA-βgal

Human EpCAM x E. coli β-Gal Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Evaluation of T cell activation (ELISA)

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-hEpCAM-βgal

Human EpCAM x Human CD3 Bispecific Antibody

Solitomab scFv antibody - Recombinant

Evaluation of T cell activation (ELISA)

Human BCMA x Human CD3 Bispecific Antibody

Pacanalotamab scFv antibody - Recombinant

Evaluation of T cell activation

Human CD70 Antibody - Vorsetuzumab IgG1fut Isotype

Human IgG1, afucosylated

Binding of Anti-hCD70-hIgG1fut mAb to hCD70

Comparison of ADCC induction of Anti-hCD70 mAbs

Human VISTA Antibody - Onvatilimab IgG1fut Isotype

Human IgG1, non-fucosylated

Binding of Anti-hVISTA-hIgG1fut to target cells

ADCC potency of native and engineered Anti-hVISTA isotype family

ADCC assay with Raji-hVISTA cells

E. coli β-Gal x Human CD3 Bispecific Antibody - Negative Control

Control scFv antibody - Recombinant

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Anti-βgal-hCD3 does not allow Jurkat-Lucia™ NFAT cell activation

Human CD19 x E. coli β-Gal Bispecific Antibody - Negative control

Control scFv antibody - Recombinant

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Absence of Jurkat-Lucia™ NFAT cell activation using Anti-βgal-hCD3

Human CD19 x Human CD3 Bispecific Antibody

Blinatumomab scFv antibody - Recombinant

Evaluation of T cell activation

Target specificity of Anti-hCD19-CD3

Jurkat-Lucia™ NFAT cell activation

Activation of Jurkat-Lucia™ NFAT cells with Anti-hCD19-CD3

Human TIGIT Antibody - Etiligimab IgG1fut Isotype

Human IgG1, afucosylated

Binding of Anti-hTIGIT-hIgG1fut to target cells

Comparison of ADCC potency for native and engineered anti-human TIGIT antibody isotypes

Human CD27 Antibody - Varlilumab IgG1fut Isotype

Human IgG1, afucosylated

Characteristics and mechanism of Anti-hCD27 biosimilar isotype family

Comparison of ADCC induction of Anti-hCD27 mAbs

Binding of Anti-hCD27-hIgG1fut mAb to hCD27

Human CD20 Antibody - Obinutuzumab Biosimilar

Human IgG1, afucosylated - CAS #949142-50-1

CD20 cell surface staining using Anti-hCD20-Ga-hIgG1fut

Human IgG1fut Isotype Control Antibody

E. coli β-Galactosidase antibody (clone T9C6) - afucosylated - Recombinant

Default product image

Human CTLA4 (CD152) Antibody - Ipilimumab IgG1fut Isotype

Human IgG1, afucosylated

ADCC assay using various anti-human CTLA-4 (Ipilimumab) antibody isotypes and Raji-hCTLA4 target cells

Human PD-L1 Antibody - Atezolizumab IgG1fut Isotype

Human IgG1, afucosylated

Comparison of ADCC potency for native and engineered anti-human PD-L1 antibody isotypes